A practical guide to the use of interferons in the management of hepatitis virus infections

Drugs

Volumn 53, Issue 1, 1997, Pages 74-85

  Saracco, Giorgio ^a   Rizzetto, Mario ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INDOMETACIN; INTERFERON; IRON; KETOPROFEN; PARACETAMOL; RIBAVIRIN; VIRUS DNA; VIRUS RNA;

ALOPECIA; ANOREXIA; ASTHENIA; CHRONIC HEPATITIS; CONVULSION; DELTA AGENT HEPATITIS; DISEASE ACTIVITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; ENVELOPE GENE; FATIGUE; FEVER; GENOTYPE; HEADACHE; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE DEFICIENCY; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER HISTOLOGY; MYALGIA; MYOCARDITIS; PSYCHOSIS; RECURRENCE RISK; REMISSION; REVIEW; RIGOR; SEROCONVERSION; THYROID DISEASE; VIREMIA;

DNA VIRUSES; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS;

EID: 0031029317     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199753010-00005     Document Type: Review

References (74)

1. Berris B, Feinman V. Thyroid dysfunction and liver injury following alpha-interferon treatment of chronic viral hepatitis. Dig Dis Sci 1991; 36: 1657-60
2. Lisker-Melman M, Di Bisceglie AM, Usala SJ, et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992; 102: 2155-60
3. Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147: 1577-80
4. McDonald EM, Mann AH, Thomas HC. Interferons as mediators of psychiatric morbidity: an investigation in a trial of recombinant alfa-interferon in hepatitis B carriers. Lancet 1987; 11: 1175-8
5. Papo T, Marcellin P, Bernuau J, et al. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 1992; 116: 51-3
6. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995; 108: 1770-7
7. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38-47
8. Renault PF. Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989; 9: 273-6
9. Roffi L, Colloredo Mels G, Antonelli G, et al. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology and management. Hepatology 1995; 21: 645-9
10. Barbera C, Bortolotti F, Crivellaro C, et al. Recombinant interferon alfa-2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. Hepatology 1994; 20: 287-90
11. Bortolotti F, Giacchino R, Vajro P, et al. Recombinant interferon-alfa therapy in children with chronic hepatitis C. Hepatology 1995; 22: 1623-7
12. Gregorio GV, Jara P, Hierro L, et al. Lymphoblastoid interferon alfa with or with out steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology 1996; 23: 700-7
13. Mayet WJ, Hess G, Gerken G, et al. Treatment of chronic typeB hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 1989; 10: 24-8
14. Saracco G, Touscoz A, Durazzo M, et al. Autoantibodies and response to alpha-interferon in patients with chronic viral hepatitis. J Hepatol 1990; 11: 339-43
15. Muratori L, Lenzi M, Cataleta M, et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994; 21: 199-203
16. Todros L, Saracco G, Durazzo M, et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology 1995; 22: 1374-8
17. Brunello MR, Giarin MM, Oliveri F, et al. Wild type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci USA 1991; 88: 4186-90
18. Perrillo RP, Brunt EM. Hepatic histologic and immunohistochemical changes in chronic hepatitis B alter prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen. Ann Intern Med 1991; 115: 113-5
19. Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114: 629-34
20. Lok AS, Chung HT, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993; 105: 1833-8
21. Hoofnagle JH, Peters MG, Mullen KD, et al. Randomized controlled trial of a four-month course of recombinant human alpha interferon in chronic type B hepatitis. Gastroenterology 1988; 95: 1318-25
22. Brook MG, Chan G, Yap I, et al. Randomised controlled trial of lymphoblastoid interferon alia in Europid men with chronic hepatitis B virus infection. BMJ 1989; 299: 652-6
23. Saracco G, Mazzella G, Rosina F, et al. A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. Hepatology 1989; 10: 336-41
24. Perrillo RP, Schiff ER, Davis GL, et al. A randomised controlled trial of interferon-alfa-2b alone and after prednisone with drawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295-301
25. Lok AS, Wu PC, Lai CL, et al. A controlled trial of interferon with or with out prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-7
26. Wong DK, Yim C, Naylor CD, et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995; 108: 165-71
27. Cohard M, Poynard T, Mathurin P, et al. Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis. Hepatology 1994; 20: 1390-8
28. Wong JB, Koff RS, Tiné F, et al. Does interferon therapy for chronic hepatitis B reduce the risks of developing cirrhosis and hepatocellular carcinoma? Ann Intern Med 1995; 122: 664-75
29. Brunetto MR, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepalology 1989; 10: 198-202
30. Hadzyiannis SJ, Bramou T, Makris A, et al. Interferon alfa-2b treatment of HBeAg negative/serum HBV-DNA positive chronic active hepatitis type B. J Hepatol 1990; 11 Suppl. 1: s133-6
31. Pastore G, Santantonio T, Milella M, et al. Anti-HBc-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol 1992; 14: 221-5
32. Fattovich G, Farci P, Rugge M, et al. A randomized controlled trial of lymphoblastoid interferon-alfa in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992; 15: 584-9
33. Hadziyannis SJ, Papaioannou C, Savvas S, et al. Long-term alpha-interferon therapy in anti-HBe positive chronic hepatitis B increases significantly the frequency of sustained response [abstract]. Hepatology 1994; 19: 701
34. Rosina F, Rizzetto M. Treatment of chronic type D (delta) hepatitis with alpha interferon. Semin Liver Dis 1989; 9: 264-6
35. Rosina F, Pintus C, Meschievitz C, et al. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 1991; 13: 1052-6
36. Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330: 88-94
37. Gaudin JL, Faure P, Codinot H, et al. The French experience of treatment of chronic type D hepatitis with a 12 month course of IFN alpha-2b: results of a randomized, controlled trial. Liver 1995; 15: 45-52
38. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of Hepatitis C Virus: quasispecies and genotypes. Semin Liv Dis 1995; 15: 41-63
39. Okamoto H, Kurai K, Okada SI, et al. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes. Virology 1992; 188: 331-41
40. Chan SW, McOmish F, Holmes FC, et al. Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. J Gen Virol 1992; 73: 1131-41
41. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-alfa therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-94
42. Mita E, Hayashi N, Hagiwara H, et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994; 39: 977-82
43. Hino K, Sainokami S, Shimoda K, et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994; 42: 299-305
44. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-6
45. Garson JA, Brillanti S, Whitby K, et al. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C. J Med Virol 1995; 45: 348-53
46. Brillanti S, Foli M, Gaiani S, et al. Persistent hepatitis C viraemia without liver disease. Lancet 1993; 341: 464-5
47. Prieto M, Olaso V, Verdú C. et al. Does the healthy hepatitis C virus carrier stale really exist? An analysis using polymerase chain reaction. Hepalology 1995; 22: 413-7
48. Alberti A, Morsica G, Chemello L, et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340: 697-8
49. Davis GL, Balart LA, Schiff FR, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501-6
50. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-10
51. Saracco G, Rosina F, Torrani Cerenzia MR, et al. A randomized controlled trial of interferon alfa-2b as therapy for chronic nonAnonB hepatitis. J Hepatol 1990; 11: S43-9
52. Weiland O, Schvarcz R, Wejstal R, et al. Therapy of chronic post-transfusion nonAnonB hepatitis with interferon alfa-2b: Swedish experience. J Hepatol 1990; 11 Suppl. 1: S57-62
53. Gomez-Rubio M, Porres JC, Castillo I, et al. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alfa-interferon in comparison with a control group. J Hepatol 1990; 11: S63-7
54. Marcellin P, Boyer N, Giostra E, et al. Recombinant human alfa-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393-7
55. Saez-Royuela F, Porres JC, Moreno A, et al. High dose of recombinant alfa-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 1991; 13: 327-31
56. Causse X, Godinot H, Chevalier M, et al. Comparison of 1 or 3 MU of interferon-alfa-2b and placebo in patients with chronic nonA, nonB hepatitis. Gastroenterology 1991; 101: 497-502
57. Diodati G, Bonetti P, Noventa F, et al. Treatment of chronic hepatitis C with recombinant human interferon-alfa2a: results of a randomized controlled clinical trial. Hepatology 1994; 19: 1-5
58. Negro F, Baldi M, Mondardini A, et al. Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology 1994; 107: 479-85
59. Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alpha-2a interferon in chronic hepatitis C. Hepatology 1995; 22: 700-6
60. Reichard O, Foberg U, Fryden A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alfa2b for 60 weeks. Hepatology 1994; 19: 280-5
61. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457-62
62. Yokosuka O, Kato N, Ito Y, et al. Efficacy of long-term interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA. Gut 1995; 37: 721-6
63. Kasahara A, Hayashi N, Hiramatsu N, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995; 21: 291-7
64. Lin R, Roach E, Zimmerman M, et al. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. J Hepatol 1995; 23: 487-96
65. Saracco G, Rosina F, Abate ML, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alfa2b. Hepatology 1993; 18: 1300-5
66. Zaaijer HL, Cuypers HTM, Reesink HW, et al. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 1993; 341: 722-4
67. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995; 15: 82-91
68. Saracco G, Rosina F, Abate ML, et al. Long-term response to interferon-alfa2b retreatment in chronic hepatitis C [letter]. J Hepatol 1994; 21: 278-9
69. Marcellin P, Pouteau M, Boyer N, et al. Retreatment with recombinant interferon-alpha in patients with chronic hepatitis C. J Infect Dis 1993; 167: 780-1
70. Kakumu S, Yoshioka K. Retreatment with interferon in patients with chronic hepatitis C [letter]. J Hepatol 1994; 21: 483
71. Andreone P, Cursaro C, Gramenzi A, et al. Alfa-interferon plus indomethacin combined therapy for non-responder patients with chronic hepatitis C [abstract]. Hepatology 1993; 18: 659
72. Andreone P, Cursaro C, Gramenzi A, et al. Pilot study of alfa-interferon and ketoprofen combined therapy in non-responder patients with chronic hepatitis C: an interim report [abstract]. Gastroenterology 1994; 106: 859
73. Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-7
74. Schvarcz R, Yun ZB, Sonnerborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 1995; 46: 43-7